Peter J. Barry

United Kingdom

Poster(s):

• (20) Impact of Elexacaftor/Tezacaftor/Ivacaftor therapy on older patients with Cystic Fibrosis
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (169) A Phase 4, Fully Decentralized Clinical Trial to Evaluate Physical Activity and Cough Frequency in Patients with Cystic Fibrosis Using Wearable Technology
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (185) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (205) Do we need a colorectal cancer screening programme for patients with cystic fibrosis?
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (220) Changes in Liver Function Tests and Liver Stiffness Measurements over 12 months in Cystic Fibrosis Patients commenced on Elexacaftor/Tezacaftor/Ivacaftor at a Large Adult Center
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET